

From the INTERNATIONAL BUREAU

**PCT**NOTIFICATION CONCERNING  
TRANSMITTAL OF COPY OF INTERNATIONAL  
PRELIMINARY REPORT ON PATENTABILITY  
(CHAPTER I OF THE PATENT COOPERATION  
TREATY)

(PCT Rule 44bis.1(c))

To:

COLEMAN, Henry, D.  
Coleman Sudol Sapone, P.C.  
714 Colorado Avenue  
Bridgeport, CT 06605-1601  
ETATS-UNIS D'AMERIQUEDate of mailing (*day/month/year*)

17 August 2006 (17.08.2006)

Applicant's or agent's file reference

Y03-097PCT

**IMPORTANT NOTICE**

International application No.

PCT/US2005/002910

International filing date (*day/month/year*)

31 January 2005 (31.01.2005)

Priority date (*day/month/year*)

03 February 2004 (03.02.2004)

Applicant

YALE UNIVERSITY et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

**RECEIVED****AUG 25 2006**

COLEMAN SUDOL SAPONE, P.C

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Athina Nickitas-Etienne

Facsimile No. +41 22 338 82 70

e-mail: pt04@wipo.int

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference Y03-097PCT	<b>FOR FURTHER ACTION</b>	See item 4 below
International application No. PCT/US2005/002910	International filing date ( <i>day/month/year</i> ) 31 January 2005 (31.01.2005)	Priority date ( <i>day/month/year</i> ) 03 February 2004 (03.02.2004)
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237		
Applicant YALE UNIVERSITY		

1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.

3. This report contains indications relating to the following items:

- |                                     |              |   |
|-------------------------------------|--------------|---|
| <input checked="" type="checkbox"/> | Box No. I    | Basis of the report   |
| <input type="checkbox"/>            | Box No. II   | Priority  |
| <input type="checkbox"/>            | Box No. III  | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  |
| <input type="checkbox"/>            | Box No. IV   | Lack of unity of invention  |
| <input checked="" type="checkbox"/> | Box No. V    | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| <input type="checkbox"/>            | Box No. VI   | Certain documents cited   |
| <input type="checkbox"/>            | Box No. VII  | Certain defects in the international application  |
| <input checked="" type="checkbox"/> | Box No. VIII | Certain observations on the international application   |

4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Date of issuance of this report 07 August 2006 (07.08.2006)
Facsimile No. +41 22 338 82 70	Authorized officer  <div style="text-align: center; font-weight: bold;">Athina Nickitas-Etienne</div> e-mail: pt04@wipo.int

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:  
HENRY D. COLEMAN  
COLEMAN SUDOL SAPONE, P.C.  
714 COLORADO AVENUE  
BRIDGEPORT, CT 06605-1601

## PCT

REC'D 18 JUL 2005

WIPO

PCT

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Applicant's or agent's file reference <b>Y03-097PCT</b>		Date of mailing (day/month/year) <b>15 JUL 2005</b> <b>FOR FURTHER ACTION</b> See paragraph 2 below
International application No. <b>PCT/US05/02910</b>	International filing date (day/month/year) <b>31 January 2005 (31.01.2005)</b>	Priority date (day/month/year) <b>03 February 2004 (03.02.2004)</b>
International Patent Classification (IPC) or both national classification and IPC <b>IPC(7): C07D 311/32; A61K 31/352 and US Cl.: 549/400; 514/451</b>		
Applicant <b>YALE UNIVERSITY</b>		

**1. This opinion contains indications relating to the following items:**

- |                                     |              |  |
|-------------------------------------|--------------|--|
| <input checked="" type="checkbox"/> | Box No. I    | Basis of the opinion   |
| <input type="checkbox"/>            | Box No. II   | Priority   |
| <input type="checkbox"/>            | Box No. III  | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability   |
| <input type="checkbox"/>            | Box No. IV   | Lack of unity of invention   |
| <input checked="" type="checkbox"/> | Box No. V    | Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| <input type="checkbox"/>            | Box No. VI   | Certain documents cited  |
| <input type="checkbox"/>            | Box No. VII  | Certain defects in the international application   |
| <input checked="" type="checkbox"/> | Box No. VIII | Certain observations on the international application  |

**2. FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

**3. For further details, see notes to Form PCT/ISA/220.**

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Rita J. Desai <i>Rita J. Desai</i> Telephone No. 703-308-1235 <i>for</i>
---	---

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US05/02910

**Box No. I Basis of this opinion**

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

☐ a sequence listing

☐ table(s) related to the sequence listing

b. format of material

☐ in written format

☐ in computer readable form

c. time of filing/furnishing

☐ contained in international application as filed.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority for the purposes of search.

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US05/02910

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims <u>1-53</u>	YES
	Claims <u>NONE</u>	NO
Inventive step (IS)	Claims <u>1-53</u>	YES
	Claims <u>NONE</u>	NO
Industrial applicability (IA)	Claims <u>1-53</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and explanations:

Claims 1-53 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the claimed invention.

Fatma U. Afifi et al teaches similar compounds but R2 of the prior art is never an O substituent and also the phenyl ring is substituted..

M.ZIA-UL-HAQ et al teaches similar compounds , see formula II on page 808 but they do not have the OH substitutions and also the phenyl ring is substituted.

Claims 1-53 meet the criteria set out in PCT Article 33(4), and thus meet the industrial applicability because the subject matter claimed can be made or used in industry.

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US05/02910

**Box No. VIII Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Drugs do not have an umbrella efficacy for treating any and all types of cancers. The specifications do not have a clear description of which cancer it treats. It is not clear how one can increase the sensitivity of tumor or cancer cells to anti cancer agents. [Claim 30]